PFM Health Sciences, LP Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001442756

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidHealth TiltHigh Turnover how tags are computed

Q2 2026 · 96 positions · Total reported value $1.14B · Top-10 concentration 34.6% · Updated 2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

Turnover: 78.2% · 32 new · 40 cut · 14 exited

Active Share (vs S&P 500): 95.8% · vs QQQ: 99.3% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +24.2% · vs SPY +9.4% · Prev Value $987.91M — last quarter positions weighted by this quarter price moves · ranking

In its Q2 2026 13F filing, PFM Health Sciences, LP disclosed 96 equity positions with a combined reported value of $1.14B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 34.6% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.

The largest disclosed positions as of Q2 2026 were ASND ($62.19M), AXSM ($53.75M), LLY ($47.09M). By sector, the heaviest allocations are Health Care 92.9%, Industrials 5.1%. Versus the prior quarter, allocation shifted toward Health Care (+8.2pp), Industrials (+3.1pp) and away from Other (-13.3pp).

Versus the prior quarter, PFM Health Sciences, LP opened 32 new positions, trimmed 40 and fully exited 14, a turnover rate of 78.2% of positions. The portfolio's overlap with the prior quarter was 58% of names.

The largest new positions opened in Q2 2026 were HUM ($37.49M), MTD ($17.05M), MRK ($16.33M).

Of the 14 positions fully exited versus the prior quarter, the largest were XBI ($58.16M), XLV ($35.03M), GKOS ($23.22M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2026)

  • HUM HUMANA INC COM · $37.49M
  • MTD METTLER TOLEDO INTERNATIONAL COM · $17.05M
  • MRK MERCK & COMPANY · $16.33M
  • CYTK CYTOKINETICS INC · $16.33M
  • LNTH LANTHEUS HOLDINGS INC · $16.24M
  • CVS CVS HEALTH CORP · $14.22M
  • GILD GILEAD SCIENCES · $11.48M
  • TFX TELEFLEX INC · $10.10M

Fully Exited (vs previous quarter)

  • XBI STATE STREET SPDR S&P BIOTECH ETF · prev qtr: $58.16M
  • XLV STATE STREET HEALTH CARE SELECT SECTOR SPDR ETF · prev qtr: $35.03M
  • GKOS GLAUKOS CORP · prev qtr: $23.22M
  • CNTA CENTESSA PHARMACEUTICALS PLC · prev qtr: $20.98M
  • NEO NEOGENOMICS INC · prev qtr: $13.24M
  • DXCM DEXCOM INC COM · prev qtr: $9.40M
  • TERN TERNS PHARMACEUTICALS INC · prev qtr: $9.12M
  • SLNO SOLENO THERAPEUTICS INC · prev qtr: $8.31M

Insider Transactions (Form 4)

Latest PFM Health Sciences, LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

PFM Health Sciences, LP is an SEC-registered 13F filer based in San Francisco, CA, United States. As of Q2 2026 it reported 96 US equity positions with a combined value of $1.14B. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: SAN FRANCISCO, CA, United States
  • SEC registration: 801-69012 (status: Approved), registered 2008-04-10
  • Regulatory AUM (Form ADV): $1.27B as of 2026-03-31
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 4 private funds, of which 2 hedge funds
  • Website: pfmhealthsciences.com

Portfolio Structure

  • 96 positions · $1.14B reported value (Q2 2026)
  • Top 10 holdings = 34.6% of reported value
  • Largest position: ASND (ASCENDIS PHARMA A/S) at 5.4%
  • Average position size: $11.89M

Sector Tilt

  • Health Care 92.9%
  • Industrials 5.1%
  • Consumer Staples 1.2%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 32 new, 24 added, 40 reduced, 14 exited

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 92.9%
Technology 0.8%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 233.17K $62.19M 5.45%
5.45%
Add
2 219.60K $53.75M 4.71%
4.71%
Reduce
3 39.26K $47.09M 4.12%
4.12%
Reduce
4 160.77K $38.74M 3.39%
3.39%
Reduce
5 94.38K $37.49M 3.28%
3.28%
New
6 88.28K $36.69M 3.21%
3.21%
Add
7 213.41K $35.97M 3.15%
3.15%
Reduce
8 308.38K $29.22M 2.56%
2.56%
Add
9 49.99K $27.09M 2.37%
2.37%
Add
10 143.22K $26.82M 2.35%
2.35%
Add
11 136.48K $23.71M 2.08%
2.08%
Add
12 126.57K $23.68M 2.07%
2.07%
Reduce
13 250.45K $22.66M 1.99%
1.99%
Reduce
14 59.83K $22.44M 1.97%
1.97%
Add
15 60.22K $19.01M 1.67%
1.67%
Reduce
16 253.36K $18.87M 1.65%
1.65%
Reduce
17 56.64K $17.83M 1.56%
1.56%
Add
18 13.34K $17.05M 1.49%
1.49%
New
19 401.21K $16.46M 1.44%
1.44%
Reduce
20 127.12K $16.33M 1.43%
1.43%
New
21 191.69K $16.33M 1.43%
1.43%
New
22 146.40K $16.24M 1.42%
1.42%
New
23 220.89K $15.84M 1.39%
1.39%
Add
24 29.31K $15.74M 1.38%
1.38%
Reduce
25 524.93K $15.50M 1.36%
1.36%
Reduce
26 158.82K $15.12M 1.32%
1.32%
Reduce
27 519.02K $14.80M 1.30%
1.30%
Add
28 28.50K $14.29M 1.25%
1.25%
Add
29 137.46K $14.22M 1.25%
1.25%
New
30 197.04K $13.66M 1.20%
1.20%
Add
31 38.58K $12.91M 1.13%
1.13%
Add
32 342.75K $12.75M 1.12%
1.12%
Add
33 265.02K $12.70M 1.11%
1.11%
Add
34 126.67K $11.84M 1.04%
1.04%
Reduce
35 121.22K $11.82M 1.03%
1.03%
Reduce
36 249.02K $11.71M 1.03%
1.03%
Add
37 90.86K $11.48M 1.01%
1.01%
New
38 101.55K $11.28M 0.99%
0.99%
Reduce
39 134.42K $11.23M 0.98%
0.98%
Reduce
40 131.67K $10.73M 0.94%
0.94%
Add
41 326.05K $10.19M 0.89%
0.89%
Reduce
42 79.71K $10.10M 0.89%
0.89%
New
43 255.33K $9.96M 0.87%
0.87%
Reduce
44 141.91K $9.90M 0.87%
0.87%
Reduce
45 224.29K $9.62M 0.84%
0.84%
Add
46 268.01K $9.48M 0.83%
0.83%
Add
47 128.29K $9.11M 0.80%
0.80%
Reduce
48 480.71K $8.32M 0.73%
0.73%
Reduce
49 1.21M $8.00M 0.70%
0.70%
Add
50 65.20K $7.76M 0.68%
0.68%
New

Holdings Prediction Model

Predicts next-quarter Top-10 holdings and weights from the fund's own historical trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through quarter T. Weights are shares of the modelled portfolio.

The next-quarter predicted Top 10 (2026-Q3) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.

Latest-Quarter Accuracy (2026-Q2)

P 50% R 50% F1 50% (modelled on 2026-Q1; 5/10 hit)

Low-confidence forecast This fund replaces about 36% of its Top-10 each quarter and backtests at F1 65% (threshold 80%). Holdings in high-turnover portfolios cannot be forecast from their own history; the figures below are illustrative.

Historical Backtest (10 quarters)

Avg precision 65% · recall 65% · F1 65% · avg rank error 2.7 · Top-10 turnover 36%

Quarter Prec. Recall F1 Predicted Top 10 Actual Top 10
2024-Q1 70% 70% 70% LLY · MRK · VRTX · ABBV · EW · HUM · BDX · MCK · THC · KRTX LLY · MRK · ABBV · EW · VRTX · THC · MCK · TLT · CNC · ISRG
2024-Q2 80% 80% 80% LLY · MRK · ABBV · EW · VRTX · THC · MCK · ISRG · TLT · CNC LLY · CYTK · QQQ · THC · MRK · VRTX · ABBV · EW · ISRG · MCK
2024-Q3 80% 80% 80% LLY · QQQ · CYTK · THC · MRK · VRTX · ISRG · ABBV · EW · MCK LLY · THC · CYTK · ABBV · VRTX · ISRG · MRK · HCA · UHS · MCK
2024-Q4 50% 50% 50% LLY · THC · CYTK · ABBV · ISRG · VRTX · MRK · HCA · UNH · ACHC LLY · IEF · THC · ABBV · MCK · VRTX · ISRG · AXSM · PEN · ARGX
2025-Q1 80% 80% 80% LLY · IEF · THC · ABBV · MCK · VRTX · ISRG · AXSM · PEN · UHS LLY · ABBV · THC · MCK · AXSM · XLV · VRTX · ISRG · PEN · SLNO
2025-Q2 70% 70% 70% LLY · XLV · ABBV · AXSM · MCK · THC · VRTX · SLNO · PEN · ISRG LLY · THC · MCK · AXSM · ISRG · PEN · SLNO · CVS · OM · DHR
2025-Q3 60% 60% 60% LLY · THC · MCK · AXSM · ISRG · PEN · CVS · SLNO · OM · DHR LLY · THC · XBI · AXSM · MCK · PEN · UTHR · ISRG · EW · HCA
2025-Q4 50% 50% 50% LLY · THC · XBI · AXSM · MCK · PEN · UTHR · ISRG · EW · COR THC · LLY · AXSM · PEN · UTHR · BBIO · ADMA · NBIX · GKOS · TMO
2026-Q1 60% 60% 60% THC · LLY · PEN · AXSM · UTHR · NBIX · TMO · ADMA · BBIO · GKOS THC · LLY · XBI · PEN · AXSM · XLV · JAZZ · NBIX · GKOS · CNTA
2026-Q2 ★ 50% 50% 50% THC · XBI · LLY · PEN · AXSM · XLV · JAZZ · NBIX · GKOS · INBX ASND · AXSM · LLY · JAZZ · HUM · UNH · NBIX · INBX · UTHR · RVMD

★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.

FAQ

What did PFM Health Sciences, LP buy in 2026-Q2?

In its 2026-Q2 13F filing, PFM Health Sciences, LP reported 96 equity positions worth $1.14B in aggregate; its largest disclosed positions were ASND ($62.19M), AXSM ($53.75M), LLY ($47.09M).

How large is PFM Health Sciences, LP's portfolio?

PFM Health Sciences, LP reported $1.14B of long equity holdings across 96 positions as of 2026-Q2. Top-10 holdings account for 34.6% of reported value.

What is PFM Health Sciences, LP's investment style?

HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/pfm-health-sciences/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →